Effects of low- and intermediate-dose DHA administration before
ischemia. Reperfused cerebral ischemia cohort (low dose:
n = 21; intermediate dose: n =
16; AA: n = 8; vehicle: n =
17). Nonreperfused cerebral ischemia cohort (intermediate dose:
n = 21; AA: n = 14; vehicle:
n = 14). (A) Dose-dependent
improvements were demonstrated in cerebral blood flow at the time of
death (24 h) after reperfused cerebral ischemia (*,
P < 0.05 for either DHA doses vs. AA or vehicle).
There was a significant increase in cerebral blood flow at death in
nonreperfused animals treated with intermediate-dose DHA (*,
P < 0.05 vs. both AA and vehicle).
(B) Dose-dependent improvements were demonstrated in
infarct volume after reperfused cerebral ischemia (Left,
**, P < 0.01 for both DHA doses vs.
AA and vehicle). Improvement was demonstrated in infarct volume after
nonreperfused cerebral ischemia (Right, *,
P < 0.05 for intermediate DHA dose vs. vehicle).
(C) There was a slight decrease in neurological deficit
scores after reperfused cerebral ischemia (Left) in the
intermediate-dose DHA-treated animals compared with AA- and
vehicle-treated animals (P = NS). There was a
significant decrease in neurological deficit scores after nonreperfused
cerebral ischemia (Right) in the intermediate-dose
DHA-treated animals compared with AA-treated animals
(P < 0.05). (D) There was a
significant decrease in mortality after reperfused cerebral ischemia
(Left) in the low- and intermediate-dose DHA-treated
animals compared with vehicle-treated animals (P <
0.05). There was a 50% decrease in mortality after nonreperfused
cerebral ischemia (Right) in the intermediate-dose
DHA-treated animals compared with vehicle-treated animals
(P = NS).